retatrutide triple agonist glp-1 gip glucagon phase 2 obesity First 3 data, a Triumph of Science! Beyond GLP-1: Retatrutide's triple-agonist mechanism

Glucagon-Like Peptide 1 Receptor Agonists and the Eye AT A GLANCE Glucagon-like peptide 1 receptor agonists (GLP-1RA) are FDA-approved for treating type 2 diabetes and are commonly used in weight loss regimens

Conclusions Small molecule GLP-1 receptor agonists represent an innovative advancement in the management of T2DM and obesity

14 Sochovsky, N

Millipore, Tokyo, Japan)

52 Contraindications GLP-1RAs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2

Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes